Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 479Carcinoma, Non-Small-Cell Lung 436Prostatic Neoplasms 278Lung Neoplasms 169Stomach Neoplasms 138Neoplasms 112Squamous Cell Carcinoma of Head and Neck 109Head and Neck Neoplasms 97Neoplasm Metastasis 93Esophageal Neoplasms 70Ovarian Neoplasms 56Pancreatic Neoplasms 41Sarcoma 39Urinary Bladder Neoplasms 38Nasopharyngeal Carcinoma 32Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 26Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

palbociclib 1Letrozole 1Fulvestrant 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hormone Receptor Positive HER-2 Negative Breast Cancer × Docetaxel × Clear all
NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Fudan University

Phase 3 Recruiting
1,736 enrolled
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡